BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SkinMedica, Inc. and New York University Enter Into License Agreement for Novel Skin Lightening Program


10/27/2009 8:02:17 AM

SAN DIEGO and NEW YORK, Oct. 26 /PRNewswire/ -- SkinMedica, Inc. and New York University announced today that they have entered into a global license agreement to develop novel products to address skin hyperpigmentation based on technology invented at NYU.

Under the terms of the agreement, SkinMedica has licensed exclusive rights to develop and market products based on the NYU technology, with a range of applications in the modulation of skin pigmentation.

About Hyperpigmentation

Hyperpigmentation is a common condition in which patches of skin become darker in color than the surrounding skin. It can affect the skin color of people of any race. Normal skin color is formed by melanin, which is produced by special cells called melanocytes in the top layer of the skin. Uneven melanin production can occur in response to hormonal changes, and may also occur with certain diseases. Another common presentation is in response to skin damage or inflammation. It is advisable for persons with pigmentary problems to visit a dermatologist for a discussion of diagnosis and treatment options, and to rule out skin cancer.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. We market and sell to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products.

SkinMedica's prescription products include VANIQA(R) (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin(R) Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.

TNS Recovery Complex(R), VANIQA(R), EpiQuin(R) Micro, and SkinMedica(R), are registered trademarks of SkinMedica, Inc and affiliates.

SkinMedica, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES